ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Aug 9, 2024
WINSTON-SALEM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported business updates and financial results for the second quarter ended June 30, 2024.
Read more at globenewswire.com
